Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240)
Bibliographic record
Abstract
OBJECTIVE: Assess the effect of subcutaneous (sc) interferon (IFN) beta-1a on evolution of gadolinium-enhancing (Gd+) lesions into chronic black holes (CBHs) in relapsing-remitting multiple sclerosis (MS). BACKGROUND: CBHs indicate irreversible axonal loss in MS. METHODS: Retrospective analysis of magnetic resonance imaging scans of patients who had monthly scans during the first 9 months of the PRISMS study and 蠅1 new T1 Gd+ lesion at Months -1 to 2/3. Images were reanalyzed to assess evolution of new Gd+ lesions at Months -1 to 2/3 into CBHs by Month 8/9. CBHs were defined as new T1 hypointense lesions (initially Gd+) persisting for 蠅6 months. Outcomes were analyzed for all patients receiving sc IFN beta-1a (44mcg and 22mcg groups combined) and placebo, and by Expanded Disability Status Scale (EDSS) categories (≤2.5, >2.5; ≤3.5, >3.5). RESULTS: 122 patients were included; mean (standard deviation [SD]) age 34.7 (7.6) years; 87 (71.3%) were female. For sc IFN beta-1a and placebo, respectively, mean (SD) number of new Gd+ lesions from Month -1 to 2/3 was 7.5 (16.5) and 8.7 (12.7); median (Q1, Q3) was 4.0 (1.0, 7.0) and 4.0 (2.0, 11.0). At Month 8/9, for sc IFN beta-1a and placebo, respectively, mean (SD) proportion of Gd+ lesions that evolved into CBHs was 12.6% (24.7%) and 19.8% (28.9%); median (Q1, Q3) was 0.0 (0.0, 12.5) and 6.3 (0.0, 28.6); p=0.033. Fewer patients had 蠅1 evolved CBH with sc IFN beta-1a (34.2%) versus placebo (55.1%; odds ratio 0.42; 95% confidence interval 0.20, 0.89; p=0.024). The treatment effect on the proportion of lesions evolving was most evident in the EDSS ≤3.5 subgroup (p=0.010). Mean (SD) volume of newly evolved CBHs was: sc IFN beta-1a, 66.0 (172.6); placebo, 118.3 (329.5) mm^3 (p=0.073). CONCLUSIONS: sc IFN beta-1a was associated with a decreased proportion of new Gd+ lesions evolving into CBHs, particularly in patients with lower disability scores. Study Support: Merck Serono SA Geneva, Switzerland, a subsidiary of Merck KGaA, Darmstadt, Germany
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".